Disease · MONDO_0005451
eating disorder
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. eating disorder. Diseases, record MONDO_0005451. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005451
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 5 of its 27 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE | CHEMBL1201178 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LISDEXAMFETAMINE | CHEMBL1201222 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DASOTRALINE | CHEMBL3301595 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| LAMOTRIGINE | CHEMBL741 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PRAMIPEXOLE | CHEMBL301265 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACAMPROSATE | CHEMBL1201293 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUPROPION | CHEMBL894 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALOXONE | CHEMBL80 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets61
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Monoamine transporter | 10 | Monoamine transporter inhibitor; Serotonin transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| SLC6A2 | Monoamine transporter | 7 | Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A3 | Monoamine transporter | 4 | Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| OPRD1 | Delta-type opioid receptor | 3 | Delta opioid receptor partial agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 2/3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 3 | Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 2/3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRM1 | Mu-type opioid receptor | 3 | Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist | Phase 2/3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
1 to 10 of 61
See all 61 targetsTrials28
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01657019 | Open Label Extension in Adults With Binge Eating Disorder (BED) | Phase 3 | 604 | 2015-12-15 | Binge Eating Disorder | LISDEXAMFETAMINE DIMESYLATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02684279 | Dasotraline Binge Eating Disorder Extension Study | Phase 3 | 533 | 2020-08-12 | Binge Eating Disorder | DASOTRALINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03107026 | A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder | Phase 3 | 491 | 2020-07-13 | Binge Eating Disorder | DASOTRALINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02009163 | Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase 3 | 418 | 2016-04-01 | Binge Eating Disorder | LISDEXAMFETAMINE DIMESYLATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01718509 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase 3 | 390 | 2014-08-21 | Binge Eating Disorder | LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01718483 | SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder | Phase 3 | 383 | 2014-07-21 | Binge Eating Disorder | LISDEXAMFETAMINE DIMESYLATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01291173 | Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder | Phase 2 | 271 | 2012-12-31 | Binge Eating Disorder | LISDEXAMFETAMINE DIMESYLATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03924193 | Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment | Phase 3 | 141 | 2024-10-17 | Binge-Eating Disorder, Obesity | LISDEXAMFETAMINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01121211 | Hormonal Factors in the Treatment of Anorexia Nervosa | Phase 2 | 90 | 2017-04-26 | Anorexia Nervosa, Eating Disorder, Anxiety, Depression | TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT03539900 | Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder | Phase 2/3 | 89 | 2023-07-24 | Binge-Eating Disorder | BUPROPION, NALTREXONE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 28
See all 28 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SPD489 vs PLACEBO: serious adverse events | 3 of 192 | 2 of 187 | 379 | NCT01718483 | Trial comparisons |
| SPD489 vs PLACEBO: serious adverse events | 1 of 181 | 2 of 185 | 366 | NCT01718509 | Trial comparisons |
| Testosterone vs Placebo: deaths from any cause | 0 of 43 | 0 of 47 | 90 | NCT01121211 | Trial comparisons |
| Testosterone vs Placebo: serious adverse events | 4 of 43 | 1 of 47 | 90 | NCT01121211 | Trial comparisons |
| NB Medication vs Placebo: deaths from any cause | 0 of 43 | 0 of 46 | 89 | NCT03539900 | Trial comparisons |
| NB Medication vs Placebo: serious adverse events | 0 of 43 | 0 of 46 | 89 | NCT03539900 | Trial comparisons |
| Vortioxetine vs Placebo: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT02528409 | Trial comparisons |
| Vortioxetine vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT02528409 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: deaths from any cause | 0 of 32 | 0 of 29 | 61 | NCT03926052 | Trial comparisons |
| LDX (Lisdexamfetamine Dimesylate) vs Placebo: serious adverse events | 0 of 32 | 0 of 29 | 61 | NCT03926052 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials25
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005451
GET https://conductscience.org/api/diseases/v1/MONDO_0005451/drugs?page=2